143 related articles for article (PubMed ID: 37888961)
1. Discovery and biological evaluation of a potent small molecule CRM1 inhibitor for its selective ablation of extranodal NK/T cell lymphoma.
Liu H; Liu M; Tian X; Wang H; Gao J; Li H; Zhao Z; Liu Y; Liu C; Chen X; Yang Y
Elife; 2023 Oct; 12():. PubMed ID: 37888961
[TBL] [Abstract][Full Text] [Related]
2. Discovery and biological evaluation of a small-molecule inhibitor of CRM1 that suppresses the growth of triple-negative breast cancer cells.
Gao J; Chu P; Liu C; Sun Z; Liu Q; Yang Y
Traffic; 2021 Jul; 22(7):221-229. PubMed ID: 34021516
[TBL] [Abstract][Full Text] [Related]
3. [Bortezomib Inhibits Extranodal Natural Killer/T Cell Lymphoma, Nasal Type by Targeting NF-κB Signaling Pathway].
Li JH; Zhang L; Feng Y; Zou LQ
Sichuan Da Xue Xue Bao Yi Xue Ban; 2019 May; 50(3):311-316. PubMed ID: 31631595
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathogenic pathways in extranodal NK/T cell lymphoma.
de Mel S; Hue SS; Jeyasekharan AD; Chng WJ; Ng SB
J Hematol Oncol; 2019 Apr; 12(1):33. PubMed ID: 30935402
[TBL] [Abstract][Full Text] [Related]
5. Predicting treatment response of patients with extranodal natural killer/T-cell lymphoma based on levels of PD-L1 mRNA and soluble PD-L1.
Feng Y; Jing C; Yu X; Cao X; Xu C
Hematol Oncol; 2020 Oct; 38(4):467-477. PubMed ID: 32515093
[TBL] [Abstract][Full Text] [Related]
6. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK/T cell lymphoma.
Feng Y; Feng X; Jing C; Yu X; Zheng Y; Xu C
Sci Rep; 2022 Jan; 12(1):36. PubMed ID: 34996890
[TBL] [Abstract][Full Text] [Related]
7. CD30 expression in extranodal natural killer/T-cell lymphoma, nasal type among 622 cases of mature T-cell and natural killer-cell lymphoma at a single institution in South China.
Feng Y; Rao H; Lei Y; Huang Y; Wang F; Zhang Y; Xi S; Wu Q; Shao J
Chin J Cancer; 2017 May; 36(1):43. PubMed ID: 28486951
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of SRPK1, a key splicing regulator, exhibits antitumor and chemotherapeutic-sensitizing effects on extranodal NK/T-cell lymphoma cells.
He C; Liu B; Wang HY; Wu L; Zhao G; Huang C; Liu Y; Shan B; Liu L
BMC Cancer; 2022 Oct; 22(1):1100. PubMed ID: 36303126
[TBL] [Abstract][Full Text] [Related]
9. Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma.
Wen H; Ma H; Cai Q; Lin S; Lei X; He B; Wu S; Wang Z; Gao Y; Liu W; Liu W; Tao Q; Long Z; Yan M; Li D; Kelley KW; Yang Y; Huang H; Liu Q
Nat Med; 2018 Feb; 24(2):154-164. PubMed ID: 29291352
[TBL] [Abstract][Full Text] [Related]
10. Traditional herbal medicine-derived sulforaphene promotes mitophagic cell death in lymphoma cells through CRM1-mediated p62/SQSTM1 accumulation and AMPK activation.
Wang H; Wang F; Wu S; Liu Z; Li T; Mao L; Zhang J; Li C; Liu C; Yang Y
Chem Biol Interact; 2018 Feb; 281():11-23. PubMed ID: 29247643
[TBL] [Abstract][Full Text] [Related]
11. The Acetyltransferase KAT5 Inhibitor NU 9056 Promotes Apoptosis and Inhibits JAK2/STAT3 Pathway in Extranodal NK/T Cell Lymphoma.
Xu L; Qin Y; Liu M; Jiao J; Tu D; Zhang M; Yan D; Song X; Sun C; Zhu F; Wang X; Sang W; Xu K
Anticancer Agents Med Chem; 2022; 22(8):1530-1540. PubMed ID: 34503423
[TBL] [Abstract][Full Text] [Related]
12. Extranodal NK/T Cell Lymphoma, Nasal Type (ENKTL-NT): An Update on Epidemiology, Clinical Presentation, and Natural History in North American and European Cases.
Haverkos BM; Pan Z; Gru AA; Freud AG; Rabinovitch R; Xu-Welliver M; Otto B; Barrionuevo C; Baiocchi RA; Rochford R; Porcu P
Curr Hematol Malig Rep; 2016 Dec; 11(6):514-527. PubMed ID: 27778143
[TBL] [Abstract][Full Text] [Related]
13. Establishment and comprehensive analysis of a new human cell line (NK-NJ) with NK-cell characteristics established from extranodal natural killer cell lymphoma/leukemia.
Liang JH; Wang WT; Du KX; Xing TY; Wang Y; Wang H; Liu L; Guo R; Shao Y; Liang J; Li Y; Shen HR; Wang L; Li JY; Xu W
Hum Cell; 2023 Mar; 36(2):835-846. PubMed ID: 36520345
[TBL] [Abstract][Full Text] [Related]
14. Clinicopathological study of pulmonary extranodal nature killer/T-cell lymphoma, nasal type and literature review.
Ding W; Wang J; Zhao S; Yang Q; Sun H; Yan J; Gao L; Yao W; Zhang W; Liu W
Pathol Res Pract; 2015 Jul; 211(7):544-9. PubMed ID: 25953340
[TBL] [Abstract][Full Text] [Related]
15. A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44
Liu C; Zhang Y; Gao J; Zhang Q; Sun L; Ma Q; Qiao X; Li X; Liu J; Bu J; Zhang Z; Han L; Zhao D; Yang Y
Drug Resist Updat; 2023 Jan; 66():100903. PubMed ID: 36463808
[TBL] [Abstract][Full Text] [Related]
16. The identification of gene signatures in patients with extranodal NK/T-cell lymphoma from a pair of twins.
Wang Y; Tan H; Yu T; Ma X; Chen X; Jing F; Zou L; Shi H
BMC Cancer; 2021 Dec; 21(1):1303. PubMed ID: 34872521
[TBL] [Abstract][Full Text] [Related]
17. The Genomics and Molecular Biology of Natural Killer/T-Cell Lymphoma: Opportunities for Translation.
de Mel S; Soon GS; Mok Y; Chung TH; Jeyasekharan AD; Chng WJ; Ng SB
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966370
[TBL] [Abstract][Full Text] [Related]
18. HKDC1 C-terminal based peptides inhibit extranodal natural killer/T-cell lymphoma by modulation of mitochondrial function and EBV suppression.
Chen Q; Feng J; Wu J; Yu Z; Zhang W; Chen Y; Yao P; Zhang H
Leukemia; 2020 Oct; 34(10):2736-2748. PubMed ID: 32203147
[TBL] [Abstract][Full Text] [Related]
19. Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.
Tsuyama N; Asaka R; Dobashi A; Baba S; Mishima Y; Ueda K; Oguchi M; Tsuji H; Hatake K; Takeuchi K
Hematol Oncol; 2018 Feb; 36(1):328-335. PubMed ID: 28695659
[TBL] [Abstract][Full Text] [Related]
20. High IL-6 expression in the tumor microenvironment is associated with poor prognosis of patients with extranodal natural / killer T-cell lymphoma (ENKTL).
Rong Q; Gao Y; Cai Q; Wang X; Bai B; Ping L; He H; Rao H; Zhang Y; Li Z; Cai Q; Jiang W; Huang H
Expert Rev Anticancer Ther; 2021 Jan; 21(1):121-127. PubMed ID: 33397158
[No Abstract] [Full Text] [Related]
[Next] [New Search]
